August 11th, 2025 | 07:00 CEST
Rheinmetall & Hensoldt disappoint! The real WINNERS of the DEFENSE BOOM: Alzchem and Almonty!
Rheinmetall and Hensoldt have disappointed stock market investors with their quarterly figures. Growth, profitability, and, in particular, order intake are lagging behind high expectations. Are the second-tier companies perhaps the real winners of the defense boom? Namely, the suppliers that can deliver to virtually every defense contractor. Take Almonty, for example. The tungsten specialist is inundated with inquiries and is set to begin operations at the largest Western mine later this year. Defense contractors can only dream of such profit margins. Analysts see more than 50% upside potential. Alzchem is also doing good business with numerous defense companies. Among other things, the German company supplies specialty chemicals for explosives. A new major shareholder is causing a stir. However, not all analysts see room for further price gains.
time to read: 4 minutes
|
Author:
Fabian Lorenz
ISIN:
RHEINMETALL AG | DE0007030009 , HENSOLDT AG INH O.N. | DE000HAG0005 , ALZCHEM GROUP AG INH O.N. | DE000A2YNT30 , ALMONTY INDUSTRIES INC. | CA0203987072
Table of contents:

"[...] China's dominance is one of the reasons why we are so heavily involved in the tungsten market. Here, around 85% of production is in Chinese hands. [...]" Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Almonty: Will the stock make noise again after the quiet period?
With its long-awaited NASDAQ listing in July, Almonty Industries' share price rally reached a temporary peak. The recent setback offers investors the chance to "reload." The investment story is likely to continue for some time to come. The quiet period is coming to an end, and the chances of prices rising again are excellent. In any case, analysts foresee significantly increasing revenues and profits for the coming years.
D.A. Davidson projects Almonty's revenue to reach CAD 120 million in the coming year. By 2028, this figure is expected to reach CAD 420 million. EBITDA is forecasted to grow from CAD 70.8 million in 2026 to CAD 261.3 million in 2028, while net income should increase from CAD 66.6 million to CAD 213.2 million. Defense companies such as Renk and Co. can only dream of such margins. Therefore, analysts highlight significant revaluation potential for the Company.
Analysts in Germany also expect Almonty's revenues to rise sharply and margins to be fantastic. GBC Research sees Almonty's revenue at CAD 154 million in 2026 and already at CAD 315 million in the following year. EBITDA is expected to climb from CAD 106 million in 2026 to CAD 222 million in 2027, and net income from CAD 93 million to CAD 212 million. Accordingly, analysts recommend buying Almonty shares with a price target of EUR 5.28.
Incidentally, analysts at B. Riley see the fair value of Almonty shares at USD 6, while their colleagues at Alliance Global Partners put it at USD 6.75.
Background: Tungsten is a critical metal, with 80% of global production coming from China. The Chinese government increasingly uses its dominance over tungsten as a geopolitical tool, since tungsten is extremely hard and indispensable for defense, technology, and other industries. Almonty already produces tungsten at a mine in Portugal. In recent years, the Company has developed the Sangdong mine in South Korea, which is scheduled to open later this year, making Almonty the largest tungsten producer in the Western world. Additionally, significant molybdenum deposits have been discovered in the Sangdong area and are planned for future extraction.
Almonty shares are currently trading at EUR 3.47, well below their high of around EUR 5 at the beginning of July. It should not be forgotten that the share price was only at EUR 1 at the start of the year. A breather is therefore healthy. However, a quick return to the high for the year would come as no surprise.
Alzchem: Analysts divided
While Almonty does not "yet" have any strategic shareholders from the ranks of defense companies or governments, this is now different for MP Materials and Alzchem, for example. The US government acquired a stake in MP Materials in July. Last week, it was reported that the Czech defense company, Czechoslovak Group, had acquired a 9.2% stake in the specialty chemicals group Alzchem. The Czechs were apparently not deterred by the 150% rise in the share price this year. Alzchem is one of the leading producers of nitroguanidine, an important precursor for the manufacture of explosives.
Analysts have recently given Alzchem mixed ratings. Berenberg is among the bulls. After the quarterly figures were published, analysts raised their target price from EUR 145 to EUR 185. Estimates for the coming years were raised, and the "Buy" recommendation was reaffirmed.
In contrast, Montega currently sees Alzchem shares as a "Hold". The SDAX company would impress with strong margin expansion. Progress is also being made on the necessary capacity expansion in Germany, and the search for a location in the US is expected to be completed in 2026. However, the share has already performed strongly and reached the analysts' fair value of EUR 140.

Rheinmetall & Hensoldt: Waiting for the super cycle
German defense companies experienced a slight setback last week. The defense boom and super cycle are not yet clearly visible in the latest figures.
Hensoldt initially reported a moderate increase in revenue from EUR 849 million to EUR 944 million in the first half of 2025. Adjusted EBITDA rose slightly from EUR 103 million to EUR 107 million, though the margin fell from 12.2% to 11.3%. The order intake is likely even more important at present. But here, too, the radar specialist failed to impress. The order volume rose only slightly from EUR 1.359 billion to EUR 1.405 billion.
Rheinmetall's figures were eagerly awaited last week. And Germany's largest defense contractor also failed to impress.
Consolidated revenue climbed noticeably in the first half of 2025 compared with the same period last year, up 24% to EUR 4.735 billion. Operating profit rose by 18% to EUR 404 million. Basic earnings per share from continuing operations improved from EUR 4.21 to EUR 5.02 in the reporting period. The capital-intensive nature of the defense industry was reflected in the operating free cash flow from continuing operations, which fell significantly from EUR -19 million to EUR -644 million. The decline was mainly due to the increase in cash-effective investments, primarily for the construction of new plants and capacity expansion at existing sites, as well as order-related inventory build-up.
In terms of order backlog as of June 30, 2025, Rheinmetall reported a significant year-over-year increase from EUR 49 billion to EUR 63 billion. However, as of March 31, 2025, the figure stood at EUR 62.6 billion, indicating that order intake in the defense sector is currently stagnating.
Almonty shares currently offer an exciting opportunity to get in or add to your portfolio. Analysts believe the stock has significant upside potential, and the opening of the Sangdong mine is the next highlight on the horizon. Tungsten itself is also likely to remain in the headlines. While Almonty has already completed its consolidation phase, this may still lie ahead for Alzchem, Rheinmetall, and Hensoldt. For the defense companies, it will be crucial that more concrete orders are finally placed in the second half of the year.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.